胸腺素α_1对鸡生长性能及免疫器官发育的影响

通过对照试验在 4日龄和 7日龄时 ,低剂量组、中剂量组和高剂量组每只鸡分别肌注 0 .0 1 5 mg·kg- 1 ,0 .0 3 mg· kg- 1 和 0 .0 6mg· kg- 1 体重剂量的胸腺素α1 ( Tα1 ) ,对照组注射等量的生理盐水。试验期为 5 6d,观察 Tα1 对鸡体重、饲料转化率、法氏囊指数、胸腺指数、和脾脏指数的影响。结果表明 :在 3 5 ,42和 5 6日龄时 ,低剂量组鸡的体重显著高于其他各组 ( P<0 .0 5 ) ,而在 1 4和 2 1日龄时各组平均体重差异不显著 ( P>0 .0 5 )。在整个试验期间 ,低剂量组的饲料报酬均高于其他三组 ;低剂量组的法氏囊指数均高于其他三组 ,并在 1 4日龄时与对照组和中剂量组差异显著 ( P <0 .0 5 ) ,而在 3 5日龄与对照组和高剂量组差异显著 ( P <0 .0 5 ) ;低剂量组的胸腺指数也高于其他三组 ,1 4日龄时与对照组差异显著 ( P <0 .0 5 ) ,而与中剂量组和高剂量组差异不显著( P>0 .0 5 ) ,但在 3 5和 5 6日龄时差异显著 ( P <0 .0 5 ) ;低剂量组的脾脏指数高于其他三组 ,且在 3 5和 5 6日龄差异显著 ( P <0 .0 5 )。

CIK细胞联合胸腺肽α-1治疗消化系恶性肿瘤65例疗效观察

目的评价CIK细胞联合胸腺肽α-1(日达仙)在消化系肿瘤治疗中的有效性及安全性。方法 65例消化系肿瘤患者均给予自体CIK细胞及日达仙治疗,观察治疗前后肿瘤标志物、CD分子及患者症状体征变化。结果治疗后患者肿瘤标志物降低,CD分子升高,除8例死亡外,其余患者症状明显改善。结论自体CIK细胞联合日达仙治疗消化系肿瘤安全有效。

胸腺肽α_1联合动脉插管化疗栓塞对原发性肝癌患者血清可溶性白细胞介素-6受体和可溶性gp130的影响

目的 :了解胸腺肽α1(thymosinalpha 1Tα1)对原发性肝癌 (PHC)患者血清可溶性白细胞介素 6受体 (sIL 6R)、可溶性gp130 (sgp130 )的影响。方法 :采用双抗体夹心ELISA法观察 10例HCC经Tα1联合动脉插管化疗栓塞(TACE)治疗后血清sIL 6R、sgp130的动态改变。结果 :PHC患者血清sIL 6R、sgp130水平较对照组 (NC组 )明显升高 ,Tα1联合TACE治疗后PHC患者生存率提高 ,治疗结束后sIL 6R、sgp130水平较单用TACE明显下降。结论 :监测sIL 6R、sgp130水平能反映HCC患者的免疫功能及判定预后 ;Tα1联合TACE能提高患者生存率。

非等间隔GM（1,1,tα）幂次时间项模型及其应用

GM(1,1,tα)幂次时间项模型是灰色GM(1,1)模型的推广.在灰色GM(1,1)模型和等间隔GM(1,1,tα)幂次时间项模型的基础上提出非等间隔GM(1,1,tα)幂次时间项模型,并对模型进行求解.讨论了GM(1,1,tα)幂次时间项模型的曲线形状、发展系数以及幂指数间的关系,研究了非等间隔GM(1,1,tα)幂次时间项模型的参数空间.将平均相对误差看成幂指数的函数,根据序列形状判断幂指数的范围,并利用粒子群算法求解幂指数.实际应用验证了所提出模型的有效性.

Clinical Study on Treatment of Advanced Non-small Cell Lung Cancer by Arsenious Acid Combined with Tα-1 Thymus Peptide and Megestrol Acetate

Objective: To observe the therape utic effect of arsenious acid combined with Tα-1 thymus peptide and megestro l acetate on advanced non-small cell lung cancer.Methods: Nintey-two patients were divided randomly into the tr eated group( n =45) and the control group( n =47). The treated group were tr eated with arsenious acid combined with Tα-1 thymus peptide and megestrol ac etate, and the control group were treated with chemotherapy in the NP protocol .Results: (1) Therapeutic effect :In the 36 patients of the treated group, 2 were evaluated as CR, 8 as PR, 9 as MR, 8 as SD and 9 as PD, the CR+PR rate being 27.7% (10/36), while in the 40 patients of the control group, the co rresponding numbers were 3, 10, 11, 9, 7 and 32.5% (13/40). Comparison between t he CR+PR rate between the two groups showed insignificant difference ( P >0.05 ). (2)Clinical benefit rate: The positive rate of Karnofsky scores in the treate d group and the control group was 44.4% and 20.0% respectively; and the positive rate of body weight in the two groups was 33.3% and 12.5% respectively, the dif ference between the two groups was significant ( all P <0.05). (3)Changes of T- cell subsets and NK cell activity: CD4 and CD4/CD8 ratio after treatment i n the treated group increased significantly ( P <0.05), while in the control group, CD3, CD4, CD4/CD8 ratio and NK cell activity all lowered significantly ( P <0.01). Comparison between the two groups after treatment showed significa nt difference in CD4, CD4/CD8 ratio and NK cell activity, with those in the trea ted group all higher than those in the control group ( P <0.01). (4)Adeverse -reaction: No serious adverse reaction was found in both two groups. (5)Media n survival period:The treated group was 30 weeks and that in the control group w as 28.5 weeks, and the difference between the two groups was insignificant ( P >0.05).Conclusion: Arsenious acid combined with Tα-1 thymus peptide and megestrol acetate was a relatively effective scheme with low toxicity in tre ating advanced NSCLC.